What is the recommended treatment and follow‑up for a patient with penile squamous cell carcinoma classified as pT1a, grade 2?

Treatment Recommendation for pT1a Grade 2 Penile Squamous Cell Carcinoma

For pT1a grade 2 penile squamous cell carcinoma, organ-sparing surgery with negative surgical margins is the recommended primary treatment, achieving a 5-year recurrence-free rate of approximately 82% while preserving penile function 1.

Primary Tumor Management

Surgical Approach

The 2023 EAU-ASCO guidelines establish organ-sparing surgery as the standard for early-stage disease like pT1a tumors 1. Your specific options include:

• Wide local excision with clinically normal-appearing skin margin around the tumor
• Glansectomy (if tumor confined to glans)
• CO2 laser ablation (acceptable for pT1a disease)

Critical surgical principle: Achieve at least 1mm histologically negative margins. The 2023 guideline data shows local recurrence rates only increase considerably when the tumor-to-margin distance is <1mm 1. Frozen section analysis should be used in cases of doubt to ensure negative margins intraoperatively.

Alternative Treatment Modalities

If you prefer non-surgical organ preservation:

• Brachytherapy: Achieves 88% penile preservation at 5 years for T1 disease, though carries 12% soft tissue necrosis risk and 9% urethral stenosis risk 2
• External beam radiation: Lower 5-year recurrence-free rate of 55.2% compared to brachytherapy's 78.6% 1

Important caveat: Organ-sparing surgery has a cumulative 5-year recurrence-free rate of 82% in case series versus 76.7% in controlled studies 1, and recent data shows 18.8% positive margin rates with organ-sparing approaches versus 9.7% with partial penectomy 3. However, local recurrences can be salvaged surgically without compromising survival in most cases.

Lymph Node Management

Risk Stratification

For pT1a grade 2 disease, you are dealing with intermediate-risk disease. The 2023 guidelines mandate invasive inguinal staging 1:

1. First: Perform inguinal ultrasound bilaterally
2. If abnormal nodes on US: Fine-needle aspiration cytology
3. If US negative and patient accepts: Offer dynamic sentinel node biopsy (DSNB) or inguinal lymph node dissection

Strong recommendation: Do not observe clinically negative groins in grade 2 disease—invasive staging is required because occult nodal metastases significantly impact survival 1.

If Nodes Are Palpable (cN+)

• Obtain image-guided biopsy confirmation
• Stage with 18F-FDG-PET CT or CT chest/abdomen to exclude distant metastases
• Proceed to inguinal lymph node dissection (open or video-endoscopic) 1

Follow-Up Protocol

While the guidelines don't specify exact intervals, the research evidence provides practical guidance:

• First 2 years: Every 3 months (peak recurrence period—median 35.2 months in one series 4)
• Years 3-5: Every 6 months
• After 5 years: Annually

At each visit, examine:

• Primary site for local recurrence
• Bilateral inguinal regions for nodal disease
• Consider inguinal ultrasound if any clinical suspicion

Key Clinical Pitfalls

1. Understaging risk: Incisional biopsy followed by ablation carries higher understaging risk than complete excision 1. Always ensure adequate tissue sampling.

2. Positive margins: The 18.8% positive margin rate with organ-sparing surgery 3 is associated with poorer overall survival. Use frozen sections liberally and accept partial penectomy if negative margins cannot be achieved.

3. Inadequate nodal staging: Grade 2 disease requires invasive nodal assessment—clinical examination alone misses occult metastases that determine prognosis 1.

4. Local recurrence complacency: While historically considered salvageable, recent large series show patients with local recurrence after glansectomy have poorer survival, challenging the assumption that recurrence doesn't affect long-term outcomes 1.

Treatment Algorithm Summary

pT1a Grade 2 pSCC
    ↓
Organ-sparing excision (≥1mm margins)
    ↓
Negative margins? → YES → Proceed to nodal staging
    ↓ NO
Re-excision or partial penectomy
    ↓
Inguinal US bilaterally
    ↓
Abnormal? → YES → FNA → If positive: ILND
    ↓ NO
Offer DSNB or ILND (patient preference after counseling)
    ↓
Close surveillance protocol

The evidence strongly supports organ preservation in pT1a disease, but only when negative margins can be reliably achieved and appropriate nodal staging is performed 1, 5.